Neoadjuvant Chemotherapy with Bevacizumab May Improve Outcome after Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Colorectal Carcinomatosis

2014/04/22 by Wim Ceelen, Yves Van Nieuwenhove, Dirk Vande Putte +1 · 1 citation
Engineering · Medicine · #Hepatocellular Carcinoma Treatment and Prognosis #Intraperitoneal and Appendiceal Malignancies #Nanoplatforms for cancer theranostics

paper · doi:10.1245/s10434-014-3713-7

openalex publication_date 2014/04/22 · crossref created 2014/04/22 · crossref issued 2014/04/23 · crossref published 2014/04/23 · crossref published-online 2014/04/23 · crossref published-print 2014/09/01 · crossref deposited 2019/08/09 · openalex created_date 2025/10/10 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/31

Citations

• Bevacizumab Doubles the Early Postoperative Complication Rate after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis of Colorectal Origin

Cited by

• Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy